Cargando…
Adaptive treatment allocation and selection in multi-arm clinical trials: a Bayesian perspective
BACKGROUND: Adaptive designs offer added flexibility in the execution of clinical trials, including the possibilities of allocating more patients to the treatments that turned out more successful, and early stopping due to either declared success or futility. Commonly applied adaptive designs, such...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8858379/ https://www.ncbi.nlm.nih.gov/pubmed/35184731 http://dx.doi.org/10.1186/s12874-022-01526-8 |
_version_ | 1784654228467220480 |
---|---|
author | Arjas, Elja Gasbarra, Dario |
author_facet | Arjas, Elja Gasbarra, Dario |
author_sort | Arjas, Elja |
collection | PubMed |
description | BACKGROUND: Adaptive designs offer added flexibility in the execution of clinical trials, including the possibilities of allocating more patients to the treatments that turned out more successful, and early stopping due to either declared success or futility. Commonly applied adaptive designs, such as group sequential methods, are based on the frequentist paradigm and on ideas from statistical significance testing. Interim checks during the trial will have the effect of inflating the Type 1 error rate, or, if this rate is controlled and kept fixed, lowering the power. RESULTS: The purpose of the paper is to demonstrate the usefulness of the Bayesian approach in the design and in the actual running of randomized clinical trials during phase II and III. This approach is based on comparing the performance of the different treatment arms in terms of the respective joint posterior probabilities evaluated sequentially from the accruing outcome data, and then taking a control action if such posterior probabilities fall below a pre-specified critical threshold value. Two types of actions are considered: treatment allocation, putting on hold at least temporarily further accrual of patients to a treatment arm, and treatment selection, removing an arm from the trial permanently. The main development in the paper is in terms of binary outcomes, but extensions for handling time-to-event data, including data from vaccine trials, are also discussed. The performance of the proposed methodology is tested in extensive simulation experiments, with numerical results and graphical illustrations documented in a Supplement to the main text. As a companion to this paper, an implementation of the methods is provided in the form of a freely available R package ’barts’. CONCLUSION: The proposed methods for trial design provide an attractive alternative to their frequentist counterparts. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at (10.1186/s12874-022-01526-8). |
format | Online Article Text |
id | pubmed-8858379 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-88583792022-02-22 Adaptive treatment allocation and selection in multi-arm clinical trials: a Bayesian perspective Arjas, Elja Gasbarra, Dario BMC Med Res Methodol Research BACKGROUND: Adaptive designs offer added flexibility in the execution of clinical trials, including the possibilities of allocating more patients to the treatments that turned out more successful, and early stopping due to either declared success or futility. Commonly applied adaptive designs, such as group sequential methods, are based on the frequentist paradigm and on ideas from statistical significance testing. Interim checks during the trial will have the effect of inflating the Type 1 error rate, or, if this rate is controlled and kept fixed, lowering the power. RESULTS: The purpose of the paper is to demonstrate the usefulness of the Bayesian approach in the design and in the actual running of randomized clinical trials during phase II and III. This approach is based on comparing the performance of the different treatment arms in terms of the respective joint posterior probabilities evaluated sequentially from the accruing outcome data, and then taking a control action if such posterior probabilities fall below a pre-specified critical threshold value. Two types of actions are considered: treatment allocation, putting on hold at least temporarily further accrual of patients to a treatment arm, and treatment selection, removing an arm from the trial permanently. The main development in the paper is in terms of binary outcomes, but extensions for handling time-to-event data, including data from vaccine trials, are also discussed. The performance of the proposed methodology is tested in extensive simulation experiments, with numerical results and graphical illustrations documented in a Supplement to the main text. As a companion to this paper, an implementation of the methods is provided in the form of a freely available R package ’barts’. CONCLUSION: The proposed methods for trial design provide an attractive alternative to their frequentist counterparts. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at (10.1186/s12874-022-01526-8). BioMed Central 2022-02-20 /pmc/articles/PMC8858379/ /pubmed/35184731 http://dx.doi.org/10.1186/s12874-022-01526-8 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Arjas, Elja Gasbarra, Dario Adaptive treatment allocation and selection in multi-arm clinical trials: a Bayesian perspective |
title | Adaptive treatment allocation and selection in multi-arm clinical trials: a Bayesian perspective |
title_full | Adaptive treatment allocation and selection in multi-arm clinical trials: a Bayesian perspective |
title_fullStr | Adaptive treatment allocation and selection in multi-arm clinical trials: a Bayesian perspective |
title_full_unstemmed | Adaptive treatment allocation and selection in multi-arm clinical trials: a Bayesian perspective |
title_short | Adaptive treatment allocation and selection in multi-arm clinical trials: a Bayesian perspective |
title_sort | adaptive treatment allocation and selection in multi-arm clinical trials: a bayesian perspective |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8858379/ https://www.ncbi.nlm.nih.gov/pubmed/35184731 http://dx.doi.org/10.1186/s12874-022-01526-8 |
work_keys_str_mv | AT arjaselja adaptivetreatmentallocationandselectioninmultiarmclinicaltrialsabayesianperspective AT gasbarradario adaptivetreatmentallocationandselectioninmultiarmclinicaltrialsabayesianperspective |